Panobinostat (LBH589)

For research use only. Not for use in humans.

目录号：S1030 别名： NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Panobinostat (LBH589) 可诱导自噬和凋亡。Panobinostat 可以有效地破坏体内 HIV 的潜伏期。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 953.44	现货
10mg	RMB 731.86	现货
50mg	RMB 2189.52	现货
200mg	RMB 5485.18	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Panobinostat (LBH589)发表文献234篇：

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 36(5):528-544

PubMed: 31631026 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):782-797

PubMed: 31085178 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nat Genet, 2018, 50(10):1442-1451

PubMed: 30224647 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 20;159(5):1110-1125.

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Commun, 2020, 11(1):583

PubMed: 31996670 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):105

PubMed: 32517809 ( click the link to review the publication )

Cancers (Basel), 2020, 5;12(6):E1478

PubMed: 32517016 ( click the link to review the publication )

PLoS Pathog, 2020, 16(3):e1008442

PubMed: 32196533 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32059481 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )
Sci Rep, 2020, 10(1):3470

PubMed: 32103105 ( click the link to review the publication )

Fluids Barriers CNS, 2020, 2;17(1):37

PubMed: 32487241 ( click the link to review the publication )

Exp Hematol, 2020, 81:32-41

PubMed: 31954171 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04021-y

PubMed: 31894347 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Cell Res, 2019, 29(4):286-304

PubMed: 30631154 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3319

PubMed: 31346162 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz215

PubMed: 31711240 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )
Breast Cancer Res, 2019, 21(1):134

PubMed: 31801577 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

J Biomed Nanotechnol, 2019, 15(5):979-992

PubMed: 30890229 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18970-18984

PubMed: 30916359 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

J Virol, 2019, 93(24)

PubMed: 31578289 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Epigenetics Chromatin, 2019, 12(1):18

PubMed: 30871586 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(12):2230-2240

PubMed: 31478563 ( click the link to review the publication )

Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )
Mol Genet Genomic Med, 2019, 7(5):e613

PubMed: 30891950 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4866

PubMed: 30451831 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Oncogene, 2018, 37(6):722-731

PubMed: 29059175 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):381-392

PubMed: 28839000 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

J Immunol, 2018, 201(3):1086-1096

PubMed: 29914885 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )
Sci Rep, 2018, 8(1):9472

PubMed: 29930256 ( click the link to review the publication )

J Proteome Res, 2018, 17(4):1436-1451

PubMed: 29564889 ( click the link to review the publication )

Biomed Pharmacother, 2018, 100:509-520

PubMed: 29494986 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

J Ethnopharmacol, 2018, 211:267-277

PubMed: 28970153 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):196-207

PubMed: 29317217 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0208147

PubMed: 30592723 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(1):61-74

PubMed: 29049036 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36530-36541

PubMed: 30559935 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28586-28598

PubMed: 29983882 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 100(1):174-187

PubMed: 29107335 ( click the link to review the publication )

Nat Commun, 2017, 8(1):728

PubMed: 28959017 ( click the link to review the publication )

Cancer Res, 2017, 77(11):3027-3039

PubMed: 28363998 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Br J Haematol, 2017, 178(5):728-738

PubMed: 28480959 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Horm Cancer, 2017, 8(4):257-267

PubMed: 28516379 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30019-30029

PubMed: 28415789 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56747-56757

PubMed: 28915627 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94569-94579

PubMed: 29212250 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )
EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Oncogene, 2016, 35(46):6026-6037

PubMed: 27157610 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2016, 3:16003

PubMed: 27626039 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Sci Rep, 2016, 6:30749

PubMed: 27480951 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

J Org Chem, 2016, 81(22):11324-11334

PubMed: 27768313 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )
Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0126566

PubMed: 26176219 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134426

PubMed: 26247786 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2088-100

PubMed: 25576920 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )
Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )
PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

靶点

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

体外研究

LBH589诱导MOLT-4和Reh细胞凋亡，这种作用具有时间和剂量依赖性。而且，LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长，处理48小时，具有剂量依赖性。与对照组细胞相比，用LBH589处理的细胞，在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关，LBH589也降低c-Myc的表达水平，具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589（10 nM）处理Reh细胞，最初增强c-Myc的表达水平，之后一直降低c-Myc的表达水平。此外，LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下，LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。^[1]此外, LBH589抑制非小细胞肺癌细胞系生长，如人类H1299,L55和A549，IC50分别为5,11和30 nM；间皮瘤细胞生长，如人类OK-6和 Ok-5，IC50分别为5和7 nM；及小细胞肺癌细胞系生长，如人类RG-1和LD-T，IC50分别为4和5 nM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	NYnFdWtKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGwMVExKM7:TR?=	MWGwMVQh\A>?		NX;veXVjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGniZ\|kzPjdyMke4OC=>
HepG2	NF7zT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfnb\|AxNTFyIN88US=>	M1fRWFAuPCCm		MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M2\Mb\|I3PzB{N{i0
HT29	MnnFSpVv[3Srb36gRZN{[Xl?	MVu1NOKhdk1?	NIPQVZQzPC15MjDo		MlzObY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkA1QMLiaNMg	MkTxNlY4ODJ5OES=
HepG2	MVrGeY5kfGmxbjDBd5NigQ>?	NEf6U\|Y2OMLibl2=	MVSyOE04OiCq		NYjlOnhUcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB{NNMgbOKh	MWWyOlcxOjd6NB?=
HCC827	M13GZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTBTHlGPS95LkWvNVAhdk1?	Mm\qO\|LDqGh?	MXLEUXNQ	MWflcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>?	MkPlNlY3PzV2OES=
A549	NW\TUGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXLUY9MOTBxMUWvNlAhdk1?	NGLnN\|c4OsLiaB?=	NIG5NZhFVVOR	M37meYVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk	NWLodXZMOjZ4N{W0PFQ>
NCI-H460	NYLST2x7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjnVXoyOC9{MD:zNEBvVQ>?	MmnZO\|LDqGh?	MULEUXNQ	NUW3OVM6\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	MVGyOlY4PTR6NB?=
J89GFP	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mk\ySG1UV8Li	NXfFSJZ7TUN3ME20PU45PSEEsTCxNk43PSCwTR?=	Mm[zNlY2PjN3Nki=
THP89GFP	MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWjNOHV4TE2VT9Mg	MnXZSWM2OD1zOT6zOEDDuSB4LkSzJI5O	MlzBNlY2PjN3Nki=
SK-NEP-1	NW\YPI5CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\STVAvODIkgKOxNE4xKM7:TR?=	MVKyOEBp	NFm1WnFFVVORwrC=	NXnFS2J7UUN3ME23Ok4{PCCwTR?=	MXeyOlE4PjJzOR?=
G401	NIDjXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHUbHQxNjBz4pETNVAvOCEQvF2=	M3nzZ\|I1KGh?	M3rJNWROW00EoB?=	NXjqOXdwUUN3ME2xOFMvODJibl2=	NX\qSWRrOjZzN{[yNVk>
SK-NEP-1	M13tcWNmdGxiVnnhZoltcXS7IFHzd4F6	MXy1NEBvVQ>?	NXSxVGFyOeLCk{Sg[C=>	NGf3d\|RFVVORwrC=	M4m5PZJm\HWlZYOgZ4VtdCC\|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>?	MW[yOlE4PjJzOR?=
G401	NIfQc4FE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M2nRSlUxKG6P	NVzxcWlUOeLCk{Sg[C=>	NWDVdllVTE2VT9Mg	NWLjZ\|FuemWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	NE\PUpMzPjF5NkKxPS=>
SK-NEP-1	Mke0RZBweHSxc3nzJGF{e2G7	M33wVVUxNzFyMDDuUS=>	NGj0cY8zPCCq	NUf6PXRYTE2VT9Mg	M{HnfIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MXSyOlE4PjJzOR?=
G401	NHHPT21CeG:ydH;zbZMhSXO\|YYm=	NGroZY02OC9zMECgcm0>	MknBNlQhcA>?	NYqxTHFUTE2VT9Mg	MX\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NX65O2xyOjZzN{[yNVk>
SK-NEP-1	NILQSIFHfW6ldHnvckBCe3OjeR?=	NWOxfWpQPTBxMUCwJI5O	NXPKN3VTOjRiaB?=	MnLQSG1UV8Li	NInzblZ{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w	MVKyOlE4PjJzOR?=
G401	M2XMSmZ2dmO2aX;uJGF{e2G7	MVq1NE8yODBibl2=	MlznNlQhcA>?	M2G4cWROW00EoB?=	NUfVWGtDe2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?=	NEL5VoczPjF5NkKxPS=>
SK-NEP-1	NYTXXFE4TnWwY4Tpc44hSXO\|YYm=	NXfmVplXPTBxMUCwJI5O	NYroOHFqOjRiaB?=	NYLneYRZTE2VT9Mg	MYnpcoR2[2W\|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=>	MWiyOlE4PjJzOR?=
G401	MoHaSpVv[3Srb36gRZN{[Xl?	MYK1NE8yODBibl2=	M3zmVFI1KGh?	M1X1NGROW00EoB?=	Mkn0bY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA>	MYOyOlE4PjJzOR?=
RPMI 8226	M3TSSGNmdGxiU4Xyeol3[WxiQYPzZZk>	M4PtdFIwPC94IH7N	MYG0PQKBkWh?		M{XnS4lv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	NVr4e2VbOjZyMECyPVI>
OPM2	NW\6XotTS2WubDDTeZJ3cX[jbDDBd5NigQ>?	MUOyM\|QwPiCwTR?=	M{\Y[\|Q56oDLaB?=		M{m5[Ilv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	M1\JUVI3ODByMkmy
U266	M3P0bWNmdGxiU4Xyeol3[WxiQYPzZZk>	NH\RbZAzNzRxNjDuUS=>	MVy0PQKBkWh?		M4ixSIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	NYXVbZZYOjZyMECyPVI>
H929	NYqzdHNnS2WubDDTeZJ3cX[jbDDBd5NigQ>?	MUeyM\|QwPiCwTR?=	MkDWOFjjiImq		M{ftRYlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	NWHnbWZKOjZyMECyPVI>
RPMI 8226	MX3BdI9xfG:\|aYOgRZN{[Xl?	M1rIZ\|TjiImwTR?=	MWqyOE81QCCq		NGjmcpJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	MmS1NlYxODB{OUK=
HCC827	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3ZRnFqOTBibl2=	MV:0PEBp	NFnHXpJFVVOR	NGPUNmpmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?=	MWqyOVk1PDZzNx?=
NCI-H23	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHwNVAhdk1?	M{DvZ\|Q5KGh?	MVrEUXNQ	MX\lcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>?	NFHCbIYzPTl2NE[xOy=>
AML3	MnfsSpVv[3Srb36gRZN{[Xl?	M4XoTlAuOSEQvF2=	M1;KNVI1yqCq		M4\ES4lv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGnJW5czPTZzMkm0NS=>
ML-1	NUji[ld[TnWwY4Tpc44hSXO\|YYm=	M4\peFAuOSEQvF2=	Mnr6NlTDqGh?		NYS4RYJEcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NU\DUoI3OjV4MUK5OFE>
RPMI-8226vr10	Mm\RSpVv[3Srb36gRZN{[Xl?	M1HIeVAuOSEQvF2=	MUWyOOKhcA>?		MknXbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NGPuO5ozPTZzMkm0NS=>
ML-1	MkOzSpVv[3Srb36gRZN{[Xl?	MnzMNUDPxE1?	NF3ESngzPMLiaB?=		NWDBPXgzcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ>	MmDVNlU3OTJ7NEG=
RPMI-8226vr10	Mo\kSpVv[3Srb36gRZN{[Xl?	M3zOdlEh\|ryP	M3mwdVI1yqCq		NULkS2tncW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB{LkWt[o9t\A>?	NGfQfFczPTZzMkm0NS=>
SK-N-BE (2)	NY\NVHdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NInCb24zPOLCiXi=		NUSwfpRzUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N	NGfxbGIzPTNyOEmxOi=>
SK-N-BE (2), PAN MK	M2TPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFLwSGczPOLCiXi=		Ml7nTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P	NFfaRWEzPTNyOEmxOi=>
SK-N-BE (2), MK PAN	M1HkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mk\5NlTjiImq		MYXJR\|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P	M2jMRlI2OzB6OUG2
SK-N-AS	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mki4NlTjiImq		NUHSfJplUUN3ME2zO{4y6oDLwsJihKkzNjRibl2=	NUDZc\|duOjV\|MEi5NVY>
SK-N-DZ	M{XFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWSyOQKBkWh?		MXjJR\|UxRTF5LkJihKnDueLCiUCuOEBvVQ>?	NInkWYkzPTNyOEmxOi=>
Caki-1	NVLvTIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHnNVAwOjVxNUCgcm0>	NXTJZYp7PDhiaB?=		NV6xOFVNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny	NYLj[XJ1OjV{N{mxPVE>
ACHN	NX;CbYJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3zbpMyOC9{NT:1NEBvVQ>?	NHLZUWo1QCCq		MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	M1;3WFI2Ojd7MUmx
769-P	NHnKWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfxbZoyOC9{NT:1NEBvVQ>?	NIHqR2Q1QCCq		NGXNOVZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	MXOyOVI4QTF7MR?=
786-O	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PCPFExNzJ3L{WwJI5O	NW\oN\|ZbPDhiaB?=		NW\XbZZzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny	NVG3UndDOjV{N{mxPVE>
Caki-1	MXfBdI9xfG:\|aYOgRZN{[Xl?	MmDLOVAhdk1?	NEDnWWo1QCCq		NFjqeYZqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	M1\4RVI2Ojd7MUmx
ACHN	NU\jTHdLSXCxcITvd4l{KEG\|c3H5	MmD3OVAhdk1?	MnrROFghcA>?		M33iNIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{	MW[yOVI4QTF7MR?=
769-P	MVvBdI9xfG:\|aYOgRZN{[Xl?	M2fHNVUxKG6P	MUi0PEBp		MWDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>?	M2HsflI2Ojd7MUmx
786-O	NHThSVBCeG:ydH;zbZMhSXO\|YYm=	MWe1NEBvVQ>?	NXmwbphOPDhiaB?=		NFrUOWJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	NIS2RokzPTJ5OUG5NS=>
Caki-1	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6yOU82OCCwTR?=	MVy0PEBp	MU\EUXNQ	M1rHOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK=	MVqyOVE4PjN3NB?=
ACHN	M{TBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\rSGQzPS93MDDuUS=>	NYrXUpFiPDhiaB?=	NFm3emRFVVOR	M2XEcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK=	NYjiTWJXOjVzN{[zOVQ>
769-P	NWfsfo9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;0S28zPS93MDDuUS=>	MVu0PEBp	M{f2bGROW09?	MVLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk	MUWyOVE4PjN3NB?=
Caki-1	M4PSbGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl?	MkPUOVAhdk1?	M1fq[VcuOTRiZB?=	NWjzN5p5TE2VTx?=	NWfSdpQ1e3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB?	MV[yOVE4PjN3NB?=
ACHN	MXfDc4xwdnliRn;ycYF1cW:wIFHzd4F6	M2TDVFUxKG6P	MoHRO{0yPCCm	NF30NXhFVVOR	MVjzeZBxemW\|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=>	M{jZVFI2OTd4M{W0
769-P	MUTDc4xwdnliRn;ycYF1cW:wIFHzd4F6	NV7xWnROPTBibl2=	Ml\LO{0yPCCm	MXjEUXNQ	NH7iUoN{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>?	MVGyOVE4PjN3NB?=
Caki-1	M{f0ZWFxd3C2b4Ppd{BCe3OjeR?=	NFn1WI02OCCwTR?=	MVS0PEBp	M1rRdmROW09?	NVn2SW0xcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MYCyOVE4PjN3NB?=
ACHN	Mnr3RZBweHSxc3nzJGF{e2G7	MUm1NEBvVQ>?	M3LPeVQ5KGh?	M{DqfmROW09?	Ml3VbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NX;IbnFzOjVzN{[zOVQ>
769-P	NI\v[HJCeG:ydH;zbZMhSXO\|YYm=	NEfr[GU2OCCwTR?=	NYLKZ5lLPDhiaB?=	NFX0NFZFVVOR	MVXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MXiyOVE4PjN3NB?=
MDA-MB-231	MXHNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	NVzUOoJGOTEEoH7N	MXezxsBl	MkTLSG1UVw>?	NXXIe2ky[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	MYWyOFgyODR7Nx?=
BT-549	M{PjfW1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>?	NYfHUZpvOTEEoH7N	M2jTTlPDqGR?	NUCwRm5RTE2VTx?=	NIXtbVlidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC=	MVSyOFgyODR7Nx?=
MCF-7	NIHjVG5Od3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl?	M3HOeFExyqCwTR?=	NGrybJU{yqCm	M1;RXWROW09?	NYrRXIVW[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	M3vNRlI1QDFyNEm3
MCF-7	MWXGeY5kfGmxbjDBd5NigQ>?	NWHqW20zPS13MDDuUS=>	NFfte28zPCCq	NH24XHJFVVOR	NUjvfZVuemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>?	NG\2fmUzPDN4NkSwOy=>
CTS	MoDORZBweHSxc3nzJGF{e2G7	MXmw5qCUPDBibl5CpC=>	M1zPZlQ5KGh?		M4W1S4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MWeyOFI1PDR{OR?=
OCI-AML3	Mn;aRZBweHSxc3nzJGF{e2G7	NYmyVYxlOOLCk{SwJI5OyqB?	MXW0PEBp		M1\mTYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MWOyOFI1PDR{OR?=
U937	MX\BdI9xfG:\|aYOgRZN{[Xl?	MUWw5qCUPDBibl5CpC=>	NH34UJA1QCCq		MVXpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NXHuNZdUOjR{NES0Nlk>
PC3	NGXJWYtCeG:ydH;zbZMhSXO\|YYm=	M{LxNVAuOTByIH7N	MXiyOE81QCCq		MULpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NW\0[HQxOjRzNkOyN\|A>
PC3-AR	NYTkUZBySXCxcITvd4l{KEG\|c3H5	NIHHNHYxNTFyMDDuUS=>	MkKyNlQwPDhiaB?=		M{nvbIlv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MmPqNlQyPjN{M{C=
PC3	NXfBUVB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV[wMVExOCCwTR?=	MlvkNlQwPDhiaB?=		M{naOIlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25?	MWGyOFE3OzJ\|MB?=
PC3-AR	MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILYNlAxNTFyMDDuUS=>	NFK0NJIzPC92ODDo		NY\3WI9NcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiC2aHWgS\|JOKHCqYYPl	NEn0[pUzPDF4M{KzNC=>
PC3	MX\GeY5kfGmxbjDBd5NigQ>?	MYCwMVExOCCwTR?=	NFOxXYQzPCCq		MVvzeZBxemW\|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?=	Mn\GNlQyPjN{M{C=
PC3-AR	MVLGeY5kfGmxbjDBd5NigQ>?	MkToNE0yODBibl2=	MmLtNlQhcA>?		NY\EV4tue3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4>	M3PDXlI1OTZ\|MkOw
OS-RC-2	NYnmc21OS2WubDDWbYFjcWyrdImgRZN{[Xl?	M2f6WVAuOTByMDDuUS=>	M4LybFI1NzR6L{eyJIg>	NHzwZVVFVVOR	M4XsboRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NWPZOVNIOjRzNES3N\|c>
OS-RC-2	M2XGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnoZWhsPTBibl2=	M2TON\|Q5KGh?	M1HVZmROW09?	MXXpcoR2[2W\|IFeyM20h[XK{ZYP0	MofXNlQyPDR5M{e=
OS-RC-2	NXq4OoM{SXCxcITvd4l{KEG\|c3H5	NGTwU2I2OCCwTR?=	NWXCUJFnPDhiaB?=	NGnUR\|hFVVOR	MUfpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M3vCbFI1OTR2N{O3
SK-N-AS	NGjYSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSw5qCUQDBibl2=	MormOFghcA>?		NH;IWnFKSzVyPUK3MlQhdk1?	M1XLc\|I1ODl6N{m5
SK-N-DZ	NHXKfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU[wSXBtOOLCk{iwJI5O	Mn\4OFghcA>?		Ml;XTWM2OD1{MT65JI5O	MVSyOFA6QDd7OR?=
SK-N-SH	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYWw5qCUQDBibl2=	Mk[1OFghcA>?		MYTJR\|UxRTd{LkOgcm0>	NGGyPGgzPDB7OEe5PS=>
SK-N-BE	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TKT\|DjiJN6MDDuUS=>	MkHBOFghcA>?		NVmwNFdpUUN3ME23OU41KG6P	MmLRNlQxQTh5OUm=
SK-N-AS	NG\X[YtCeG:ydH;zbZMhSXO\|YYm=	NYLYd4FrOOLCk{iwJI5O	NX\NNWVYPDhiaB?=		Mn:4dI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	NHfvc5gzPDB7OEe5PS=>
SK-N-DZ	NUDHOHE{SXCxcITvd4l{KEG\|c3H5	NUHxZ21NOOLCk{iwJI5O	M{jQflQ5KGh?		MlSzdI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	MX6yOFA6QDd7OR?=
SK-N-SH	NG\sdXNCeG:ydH;zbZMhSXO\|YYm=	MVGw5qCUPDBibl2=	NX7pdGhRPDhiaB?=		Mk\FdI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	Mn\qNlQxQTh5OUm=
SK-N-BE	M33rdmFxd3C2b4Ppd{BCe3OjeR?=	MkHWNQKBmzRyIH7N	MWO0PEBp		MU\wc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36=	Mn7RNlQxQTh5OUm=
SK-N-AS	MoDhSpVv[3Srb36gRZN{[Xl?	NXrUO3pZOOLCk{iwJI5O	NIjGcIs1QCCq		NVn6XIdocW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	MViyOFA6QDd7OR?=
SK-N-DZ	MYnGeY5kfGmxbjDBd5NigQ>?	MV6w5qCUQDBibl2=	NWSzPYdlPDhiaB?=		M3\FOIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	M3nVZVI1ODl6N{m5
SK-N-SH	MVzGeY5kfGmxbjDBd5NigQ>?	NVrETYhHOOLCk{SwJI5O	MofXOFghcA>?		NXnkNYVKcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	NYH5[GViOjRyOUi3PVk>
SK-N-BE	M2jMcWZ2dmO2aX;uJGF{e2G7	M1;vclDjiJN2MDDuUS=>	NEPUOYU1QCCq		MYTpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG\|ZTCzJIFv\CCSQWLQ	M4nhdlI1ODl6N{m5
HCC-LM3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL4eYcyNTFyMECgcm0>	NFzWc2EzPC92OD:3NkBp	MX\EUXNQ	M3;JN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3HSeFI1ODl\|OUW2
HepG2	M{HzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XabVEuOTByMDDuUS=>	NGfaRoQzPC92OD:3NkBp	MXHEUXNQ	MoS3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NF7h[m4zPDB7M{m1Oi=>
SMMC-7721	NECzb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL4OIY3OS1zMECwJI5O	MXiyOE81QC95MjDo	NXfGU4k1TE2VTx?=	NIK4OIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NV:4WWJ7OjRyOUO5OVY>
HCC-LM3	NHjMdJhCeG:ydH;zbZMhSXO\|YYm=	M3ftTVUxKG6P	NGLhW2Q1QCCq	MYXEUXNQ	NXvJbHk1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG\|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl?	NEn2XYgzPDB7M{m1Oi=>
HepG2	MoHkRZBweHSxc3nzJGF{e2G7	MnLXOVAhdk1?	NHThbFc1QCCq	M3jac2ROW09?	M3\ke4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	M4fTbFI1ODl\|OUW2
SMMC-7721	NF7RW\|NCeG:ydH;zbZMhSXO\|YYm=	M37kfVUxKG6P	NVPFTVk5PDhiaB?=	MYjEUXNQ	MYDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG\|ZYOgN{whQCCjbnSgPS=>	NWnpXG1DOjRyOUO5OVY>
HCC-LM3	NIPzWIlHfW6ldHnvckBCe3OjeR?=	MV21NE8yODBibl2=	MYGyOEBp	NXPvWnQ{TE2VTx?=	NGrwNGxl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR\|IHHu[EBxNUGtdNMg	NHTMc4QzPDB7M{m1Oi=>
HepG2	M{mxcWZ2dmO2aX;uJGF{e2G7	Mn7COVAwOTByIH7N	NXnSc4Z{OjRiaB?=	Mk[ySG1UVw>?	MlWx[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?=	M2Xhd\|I1ODl\|OUW2
SMMC-7721	M4TJc2Z2dmO2aX;uJGF{e2G7	MXq1NE8yODBibl2=	MV6yOEBp	MUTEUXNQ	NH;JU2Jl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR\|IHHu[EBxNUGtdNMg	NIX4O3IzPDB7M{m1Oi=>
HCC-LM3	MojSSpVv[3Srb36gRZN{[Xl?	M3HoWVUxNzFyMDDuUS=>	NVS4TIFMOjRiaB?=	NUewco56TE2VTx?=	NFq0PXFld3ewcnXneYxifGW\|IFLjcE15VCCneIDy[ZN{cW:w	MX[yOFA6Ozl3Nh?=
HepG2	NEHrSYFHfW6ldHnvckBCe3OjeR?=	MXG1NE8yODBibl2=	MV6yOEBp	MVfEUXNQ	M1rUcoRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25?	NF3FTGQzPDB7M{m1Oi=>
SMMC-7721	NHHpbm5HfW6ldHnvckBCe3OjeR?=	Ml\tOVAwOTByIH7N	M2PVRVI1KGh?	MnezSG1UVw>?	NXr0VnZL\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?=	NXPuTWRxOjRyOUO5OVY>
FaDu	NFHmb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:xNFDjiIWwTR?=	NF7SXGc5NzFyL{GyJIg>		M3r0VYRqe3CuYYnl[EBiKHOrZ37p[olk[W62IHHu[EBxem:ub37n[YQhTzJxTTDhdpJme3RiYYSgPEBidmRiMUNihKVpKHCxc4SgdoVt\WG\|ZR?=	MWmyOFAzPjR6Mh?=
FaDu	NXnHNplNTnWwY4Tpc44hSXO\|YYm=	M3TufFExOOLChX7N	NHSwSoozNzRxOD:xNkBp		NVzvNZRMcW6mdXPl[EBxOjGZYX[xM2NqeDIEoHX4dJJme3Orb36=	M{\qfFI1ODJ4NEiy
PC-3	Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKwMVExKM7:TR?=	MYWyOE81QC95MjDo		M1;aT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NUPOcpVIOjN7OUGyNVY>
LNCaP	M1;uWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYKwMVUh\|ryP	MmHyNlQwPDhxN{KgbC=>		NEf4XHVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MV2yN\|k6OTJzNh?=
RWPE-1	NHzvSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mki1NE0zOCEQvF2=	MYCyOE81QC95MjDo		M1THcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MnLGNlM6QTF{MU[=
Capan-1	NIjQTXhHfW6ldHnvckBCe3OjeR?=	MoTlNlUwPTBxMUCwJI5O	MojVPE8zPC92ODDo	NIXneI9FVVOR	MVTkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	MYeyN\|kzOjh6Nh?=
L3.6pl	MXjGeY5kfGmxbjDBd5NigQ>?	NF\sc\|kzPS93MD:xNFAhdk1?	Mn\pPE8zPC92ODDo	NWX6e\|BjTE2VTx?=	Mlj3[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO\|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?=	NIPIcmczOzl{Mki4Oi=>
CFPAC-1	MlG0SpVv[3Srb36gRZN{[Xl?	M3vZZlI2NzVyL{GwNEBvVQ>?	MnS4PE8zPC92ODDo	M1Plc2ROW09?	NIXBVGxld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n	MUmyN\|kzOjh6Nh?=
Capan-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnYcVQzPS93MD:xNFAhdk1?	MkG0OFghcA>?	MVXEUXNQ	NHO0Tldz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NFH4cI0zOzl{Mki4Oi=>
L3.6pl	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkL0NlUwPTBxMUCwJI5O	MXy0PEBp	NFnRWnhFVVOR	NFrrV2Fz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NX7R[2M2OjN7MkK4PFY>
CFPAC-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLKUGYzPS93MD:xNFAhdk1?	MkfJOFghcA>?	NUfSXlZETE2VTx?=	NUe1SmVWemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M3vyNFI{QTJ{OEi2
Capan-1	M4TRPWFxd3C2b4Ppd{BCe3OjeR?=	NYTWR2RoOjVxNUCvNVAxKG6P	MWW0PEBp	MUTEUXNQ	NF\CeZVqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MnHSNlM6OjJ6OE[=
L3.6pl	NIrKVplCeG:ydH;zbZMhSXO\|YYm=	MoPnNlUwPTBxMUCwJI5O	NIf4RVI1QCCq	NWr2SHllTE2VTx?=	NV3DO2tqcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M4TsRlI{QTJ{OEi2
CFPAC-1	M3PhOWFxd3C2b4Ppd{BCe3OjeR?=	NXflW3VNOjVxNUCvNVAxKG6P	NFPXdWk1QCCq	MVnEUXNQ	NIrRTIpqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NXXs[29UOjN7MkK4PFY>
HN22	NGmzSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPrRnlXOC1{MDDuUS=>	M3H4clI1NzR6IHi=	MXzEUXNQ	NILyXFhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz	NIDoTY0zOzh5N{KzOS=>
HSC4	M3XQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPYb5RpOC1{MDDuUS=>	NHvjSFUzPC92ODDo	NGDtRnVFVVOR	MXrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy	MYmyN\|g4PzJ\|NR?=
HN22	MoXlRZBweHSxc3nzJGF{e2G7	MYGwMVIxKG6P	NETydog1QCCq	NHTXXnlFVVOR	NXG0UXh5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NX;vXVVnOjN6N{eyN\|U>
HSC4	M1\5bGFxd3C2b4Ppd{BCe3OjeR?=	MUSwMVIxKG6P	NX62[29KPDhiaB?=	MV3EUXNQ	MknObY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M3LpPFI{QDd5MkO1
HN22	NUnXb49TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\OZ4kxNTJyIH7N	NXnuRWRrPDhiaB?=	MoHhSG1UVw>?	NEXWW5FqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA>	NU\6Z4hxOjN6N{eyN\|U>
HSC4	M3jGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUCyUI9HOC1{MDDuUS=>	Mlu3OFghcA>?	NXTudHpzTE2VTx?=	MkXRbY5lfWOnczDHNUBxcGG\|ZTDj[YxtKGO7Y3zlJIFzemW\|dNMg	NGn2d2szOzh5N{KzOS=>
HN22	MXzGeY5kfGmxbjDBd5NigQ>?	NUPJUFdDOC1{MDDuUS=>	MV:0PEBp	MYrEUXNQ	NF73bIV{fXCycnXzd4V{KFOyMTDlfJBz\XO\|aX;uxsA>	NXjB[2dDOjN6N{eyN\|U>
HSC4	M2HB[2Z2dmO2aX;uJGF{e2G7	M1;hWFAuOjBibl2=	NV2xOZlPPDhiaB?=	MUfEUXNQ	MVPzeZBxemW\|c3XzJHNxOSCneIDy[ZN{cW:wwrC=	NVTmRWRSOjN6N{eyN\|U>
Cal62	NHXKSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;2PWN4UUN3ME2zN{DDuSB2IH7N	M1H0U\|I{QDJ2ME[0
Hth7	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTF3INMxJFIhdk1?	NIWwNVUzOzh{NEC2OC=>
Hth83	M1rBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmS1TWM2OD1\|NDFCtUA2KG6P	MWeyN\|gzPDB4NB?=
C643	NH[1SJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTdzINMxJFExKG6P	MUGyN\|gzPDB4NB?=
SW1736	M2T5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\OZ21WUUN3ME2zOUDDuSB6IH7N	Mny2NlM5OjRyNkS=
T241	MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV33PJV2UUN3ME22OUDDuSB5IH7N	MVeyN\|gzPDB4NB?=
T351	M4TKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTVyINMxJFExKG6P	NXnBcohzOjN6MkSwOlQ>
BHP2-7	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnH5TWM2OD1\|NzFCtUA3KG6P	NELlfY8zOzh{NEC2OC=>
T238	NGjVd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j2VmlEPTB;MTy1NFAhyrFiMkCwJI5O	NWW0Z5hpOjN6MkSwOlQ>
HCT8	M1ro[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1LzTVczKGh?	NXexfWdzTE2VTx?=	MVTJR\|UxRTF{LkpihKnDueLCiUGuPUBvVQ>?	NXfTNVI6OjN{OUmzPFg>
H630	NV\nXIxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWq3NkBp	Ml;3SG1UVw>?	MmnoTWM2OD1zMj605qCKyrIkgJmzMlEhdk1?	M1vUfVI{Ojl7M{i4
cH630 5-FU-res	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX:3NkBp	M{PSSmROW09?	NVTPPII4UUN3ME2xOU426oDLwsJihKkyNjJibl2=	M1\iWFI{Ojl7M{i4
HCT116	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1HP[FczKGh?	MVnEUXNQ	M2TzZWlEPTB;MUCuO-KBkcLz4pEJNk4zKG6P	NXPEe5VzOjN{OUmzPFg>
HCT116 p53−/−	M4LQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkfxO\|IhcA>?	MVvEUXNQ	MWjJR\|UxRThwNvMAjeKy6oDLMT63JI5O	M1;POlI{Ojl7M{i4
dHCT116 p21−/−	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUTk[5hpPzJiaB?=	NIfl[3dFVVOR	NHvxWohKSzVyPUWuPgKBkcLz4pEJNU4{KG6P	NH\CNYUzOzJ7OUO4PC=>
HT29	NW\jcGhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnjBO\|IhcA>?	NVnSdm1ETE2VTx?=	NG\QUFdKSzVyPUG2MlPjiIoEsfMAjVIvOyCwTR?=	Mn7BNlMzQTl\|OEi=
LoVo	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{Pt[\|czKGh?	MXTEUXNQ	M3S0W2lEPTB;NT6x5qCKyrIkgJmwMlYhdk1?	NUPPe5N5OjN{OUmzPFg>
RKO	NXmxV4hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2izZ\|czKGh?	MnzXSG1UVw>?	NIfkZ2tKSzVyPUeuPgKBkcLz4pEJNk4zKG6P	NVWwOJNDOjN{OUmzPFg>
SW480	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlXhO\|IhcA>?	NIfj[2dFVVOR	M1jweWlEPTB;MUeuOgKBkcLz4pEJNE45KG6P	Mlm2NlMzQTl\|OEi=
eSW620	NYnKe\|JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3vpdVczKGh?	MX;EUXNQ	MmPuTWM2OD17LkJihKnDueLCiUKuNUBvVQ>?	MXGyN\|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

体内研究

LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长，与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多，说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射，每周持续5天，导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比，LBH589作用于H526衍生的肿瘤下降53%，作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%，作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下，LBH589 作用于NSCLC和Meso衍生的移植瘤，导致SCLC衍生的肿瘤中有两种衰退，伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm³降低到实验结束时的116 mm³，RG-1衍生的平均肿瘤尺寸从实验开始时的185mm³降低到实验结束时的86 mm³。^[2]

细胞实验：^[1]	- 合并 Cell lines: MOLT-4细胞和Reh(前体B细胞) Concentrations: 50 nM Incubation Time: 48小时 Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色，然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×10⁴个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比，根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 携带10×10⁶个M30细胞或5×10⁶个A549细胞的SCID鼠 Dosages: 10 mg/kg, 20 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+48% PEG 300+2% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Panobinostat (LBH589) SDF

分子量	349.43
化学式	C₂₁H₂₃N₃O₂
CAS号	404950-80-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	NVP-LBH589

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04341311	Not yet recruiting	Drug: Marizomib\|Drug: Panobinostat	Diffuse Intrinsic Pontine Glioma\|Pediatric Brainstem Glioma\|Pediatric Brainstem Gliosarcoma Recurrent\|Pediatric Cancer\|Pediatric Brain Tumor\|Diffuse Glioma	Dana-Farber Cancer Institute\|Celgene\|Secura Bio	May 2020	Phase 1
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT04326764	Recruiting	Drug: Panobinostat	Acute Myeloid Leukaemia (AML)\|Myelodysplastic Syndromes (MDS)	Goethe University\|Jan J. Cornelissen (HOVON-SAKK)\|Sebastian Giebel (PALG)	July 24 2018	Phase 3
NCT03515915	Unknown status	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound for in vivo mice study?
回答：
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

选择性强的HDAC抑制剂

RGFP966 : HDAC3-selective, IC50=80 nM.
选择性强的HDAC抑制剂

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

Panobinostat (LBH589)

客户使用Selleck生产的Panobinostat (LBH589)发表文献234篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Panobinostat (LBH589) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

技术支持

常见问题及建议解决方法

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品